LOKELMATM Sodium Zirconium Cyclosilicate

SWIFT* K+ REDUCTION AFTER ONE HOUR.1,2
SUSTAINED K+ CONTROL FOR UP TO ONE YEAR
WHEN USED AS A MAINTENANCE THERAPY.†1
NOW IN YOUR HANDS.
New, highly-selective LOKELMA (sodium zirconium cyclosilicate)
is indicated for the treatment of hyperkalaemia in adult patients1

*In an emergency situation, standard of care should be used in line with local or national guidelines
Clinical trials with LOKELMA have not included exposure longer than one year

Product Information

Dosing

LOKELMA is a daily treatment option for hyperkalaemia, with a correction phase and maintenance phase.1

Correction phase

Recommended starting dose for adults and elderly is 10 g, administered orally, three times daily as a suspension in water, with or without food. LOKELMA should be administered at least 2 hours before or 2 hours after oral medications with gastric pH-dependent bioavailability. LOKELMA can be co-administered without spacing of dosing times with oral medications that do not exhibit pH-dependent bioavailability.1

*Illustrative only. The first dose of LOKELMA should be administered as soon as hyperkalaemia is identified when clinically indicated.
In an emergency situation, standard of care should be used in line with local or national guidelines.

Dose 10 g three times daily to initiate treatment for hyperkalaemia
Dose 10 g three times daily to initiate treatment for hyperkalaemia
  • Typically, normokalaemia is achieved within 24 to 48 hours1
  • If the patient is still hyperkalaemic after 48 hours of treatment the same regimen (10 g orally three times daily)
    can be continued for an additional 24 hours1
  • When normokalaemia is achieved, the maintenance regimen should be followed1
  • If normokalaemia is not achieved after 72 hours of treatment other treatment options should be considered1

Maintenance phase

Recommended starting dose for adults and elderly is 5 g once daily.1

Maintain normokalaemia1

Dosing in the maintenance phase to treat hyperkalaemia
Dosing in the maintenance phase to treat hyperkalaemia
  • Establish the minimal effective dose to prevent recurrence of hyperkalaemia1
  • Recommended starting dose of 5 g once daily, with possible titration up to 10 g once daily, or down to 5 g once every other day, as needed, to maintain normal K+ level1
  • No more than 10 g once daily should be used for maintenance therapy1

Additional dosing and monitoring information:

  • Monitor serum K+ levels regularly during treatment. Monitoring frequency will depend on factors such as other medications, progression of chronic kidney disease and dietary K+ intake. Discontinue and re-evaluate patient
    if severe hypokalaemia occurs1
  • Safety and efficacy has not been established in children and adolescents (<18 years of age)
  • Avoid during pregnancy1
  • No dose adjustment is required for renal/hepatic impairment1
  • No data is available for use in the dialysis population1
  • Clinical trials with LOKELMA have not included exposure longer than 1 year1